Securities Fraud Suit Targets Beta Bionics

Investors have filed a federal securities class action, Holtzman v. Beta Bionics, Inc. et al., No. 2:26-cv-09999 (C.D. Cal.), for purchasers of Beta Bionics stock from July 30, 2025 through February 24, 2026. The Irvine, California company markets the iLet Bionic Pancreas as its only commercialized product. Shares fell from a class-period high of $31.99 to under $9.00 by April 10, 2026, about $23.09 per share or 72%. management called an FDA Form 483 "primarily related to our customer complaint handling system," said it was "not unusual in our industry," and CEO Sean Saint said it "had nothing to do with the actual complaints being received" and concerned "solely with the definition the reports being filed as complaints." The complaints allege those assurances were misleading because the company concealed thousands of iLet safety complaints, including life-threatening hypoglycemic events, and failed to investigate or report some incidents. When the FDA published its January 28, 2026 warning letter on February 24, 2026, the agency wrote the firm "failed to adequately analyze quality data, such as complaints, to identify existing and potential causes of nonconforming product or other quality problems," and cited failures on corrective actions and required injury reporting. Hagens Berman partner Reed Kathrein said the firm is focused on whether Beta Bionics "may have intentionally misled investors by placing revenues ahead of patient safety." The claims remain allegations in litigation. Investors seeking lead-plaintiff status have until November 3, 2026.